CureVac N.V.
CureVac N.V. Fundamental Analysis
CureVac N.V. (5CV.F) shows moderate financial fundamentals with a PE ratio of 7.06, profit margin of 1.82%, and ROE of 18.40%. The company generates $0.1B in annual revenue with moderate year-over-year growth of 8.96%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 71.1/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze 5CV.F's fundamental strength across five key dimensions:
Efficiency Score
Excellent5CV.F demonstrates superior asset utilization.
Valuation Score
Excellent5CV.F trades at attractive valuation levels.
Growth Score
Moderate5CV.F shows steady but slowing expansion.
Financial Health Score
Excellent5CV.F maintains a strong and stable balance sheet.
Profitability Score
Weak5CV.F struggles to sustain strong margins.
Key Financial Metrics
Is 5CV.F Expensive or Cheap?
P/E Ratio
5CV.F trades at 7.06 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 5CV.F's PEG of -0.24 indicates potential undervaluation.
Price to Book
The market values CureVac N.V. at 1.04 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 7.12 times EBITDA. This is generally considered low.
How Well Does 5CV.F Make Money?
Net Profit Margin
For every $100 in sales, CureVac N.V. keeps $1.82 as profit after all expenses.
Operating Margin
Core operations generate 2.12 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $18.40 in profit for every $100 of shareholder equity.
ROA
CureVac N.V. generates $11.31 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
CureVac N.V. generates limited operating cash flow of $-120.14M, signaling weaker underlying cash strength.
Free Cash Flow
CureVac N.V. generates weak or negative free cash flow of $-125.09M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.56 in free cash annually.
FCF Yield
5CV.F converts -13.76% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
7.06
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.24
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.04
vs 25 benchmark
P/S Ratio
Price to sales ratio
12.85
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.04
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.70
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.18
vs 25 benchmark
ROA
Return on assets percentage
0.11
vs 25 benchmark
ROCE
Return on capital employed
0.17
vs 25 benchmark
How 5CV.F Stacks Against Its Sector Peers
| Metric | 5CV.F Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 7.06 | 28.54 | Better (Cheaper) |
| ROE | 18.40% | 738.00% | Weak |
| Net Margin | 182.11% | -43982.00% (disorted) | Strong |
| Debt/Equity | 0.04 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 3.70 | 2806.01 | Strong Liquidity |
| ROA | 11.31% | -14624.00% (disorted) | Strong |
5CV.F outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews CureVac N.V.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
2459.85%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
235.28%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
197.56%
Industry Style: Defensive, Growth, Innovation
High Growth